Alignment Healthcare (NASDAQ:ALHC) Stock Rating Lowered by Wall Street Zen

Alignment Healthcare (NASDAQ:ALHC) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other research analysts have also recently issued research reports about the company. KeyCorp restated an “overweight” rating on shares of Alignment Healthcare in a research report on Wednesday, June 10th. Zacks Research cut shares of Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Weiss Ratings raised shares of Alignment Healthcare from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. Raymond James Financial set a $22.00 price objective on shares of Alignment Healthcare in a research note on Thursday, May 7th. Finally, Barclays decreased their target price on shares of Alignment Healthcare from $19.00 to $16.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 26th. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $24.30.

Alignment Healthcare Stock Performance

Shares of NASDAQ:ALHC opened at $14.85 on Friday. The business’s 50 day simple moving average is $19.70 and its 200 day simple moving average is $19.75. Alignment Healthcare has a 1 year low of $12.91 and a 1 year high of $25.12. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.70 and a quick ratio of 1.70. The company has a market capitalization of $3.07 billion, a P/E ratio of 78.16, a P/E/G ratio of 1.98 and a beta of 1.10.

Alignment Healthcare (NASDAQ:ALHC) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.04. The firm had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.31 billion. Alignment Healthcare had a return on equity of 20.02% and a net margin of 0.89%.The company’s quarterly revenue was up 31.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.07 EPS. On average, research analysts anticipate that Alignment Healthcare will post 0.2 EPS for the current fiscal year.

Insider Transactions at Alignment Healthcare

In related news, CEO John E. Kao sold 298,000 shares of the company’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $19.86, for a total transaction of $5,918,280.00. Following the completion of the sale, the chief executive officer directly owned 1,088,766 shares in the company, valued at $21,622,892.76. This represents a 21.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Dawn Christine Maroney sold 30,000 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $19.55, for a total value of $586,500.00. Following the sale, the president owned 947,313 shares of the company’s stock, valued at approximately $18,519,969.15. This represents a 3.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 1,039,951 shares of company stock worth $19,976,967. 5.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ALHC. Vanguard Group Inc. boosted its stake in shares of Alignment Healthcare by 10.9% in the 4th quarter. Vanguard Group Inc. now owns 15,492,802 shares of the company’s stock valued at $305,983,000 after purchasing an additional 1,524,218 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Alignment Healthcare by 26.9% during the 4th quarter. Wellington Management Group LLP now owns 14,070,893 shares of the company’s stock valued at $277,900,000 after purchasing an additional 2,981,166 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in Alignment Healthcare by 0.6% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,643,784 shares of the company’s stock worth $249,715,000 after purchasing an additional 79,268 shares in the last quarter. Invesco Ltd. increased its position in Alignment Healthcare by 38.9% during the 4th quarter. Invesco Ltd. now owns 6,202,592 shares of the company’s stock worth $122,501,000 after purchasing an additional 1,735,962 shares in the last quarter. Finally, 8 Knots Management LLC lifted its stake in Alignment Healthcare by 6.4% in the 2nd quarter. 8 Knots Management LLC now owns 5,015,881 shares of the company’s stock valued at $70,222,000 after purchasing an additional 300,409 shares during the last quarter. Institutional investors and hedge funds own 86.19% of the company’s stock.

Trending Headlines about Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Q2 results exceeded expectations: Alignment reported adjusted earnings of $0.17 per share, above the $0.13 consensus estimate, while revenue of $1.34 billion surpassed estimates of $1.31 billion. Revenue increased 31.6% year over year, and net income more than doubled to $36.6 million as Medicare Advantage care costs improved. Alignment Healthcare Reports Second Quarter 2026 Results
• Positive Sentiment: Operating performance is improving: The company said it surpassed the high end of its guidance across key metrics, reflecting stronger membership growth, revenue, and profitability compared with the prior-year period. Alignment Healthcare Turns Profit
• Neutral Sentiment: Guidance remained broadly in line: Full-year 2026 revenue guidance was approximately $5.2 billion, and third-quarter revenue guidance was approximately $1.3 billion, generally matching analyst expectations. The lack of a material forecast increase may have limited the earnings-driven upside.
• Negative Sentiment: Several law firms announced investigations: Frank R. Cruz, Block & Leviton, Kaplan Fox, Lowey Dannenberg, and Pomerantz publicized inquiries into possible securities-law violations and alleged financial manipulation. The investigations follow an earlier sharp drop in ALHC shares and could create legal costs, reputational damage, and uncertainty regarding the company’s disclosures. The allegations have not been proven. Securities Fraud Investigation Into Alignment Healthcare

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.